Enacademic 🎓Analogindex
49 subscribers
77.3K photos
5 videos
249K links
Download Telegram
*After a lot of people in this sub have finally finished the game do you think giving Starfield a 10/10 is justifiable?*

submitted by /u/Touny420 to r/Starfield [link] [comments]
[Read more...](https://www.reddit.com/r/Starfield/comments/16ykzk2/after_a_lot_of_people_in_this_sub_have_finally/)
After a lot of people in this sub have finally finished the game do you think giving Starfield a 10/10 is justifiable?

submitted by /u/Touny420 to r/Starfield link comments
Read more...
*Как избавиться от чёрных точек и не навредить при этом коже*

Возможно, то, что вы видите, вовсе и не чёрные точки.
[Read more...](https://burninghut.ru/chernye-tochki/?utm_source=lifehacker.ru&utm_medium=referral&utm_campaign=teaser&utm_content=chernye-tochki)
*Point Biopharma stock soars on $1.4B takeover bid from Eli Lilly*

Point Biopharma Global (PNT) - Get Free Report shares soared in premarket trading after the radiation-therapies experts agreed to a $1.4 billion takeover by pharma giant Eli Lilly (LLY) - Get Free Report. Eli Lilly said it will pay $12.50 per share in cash for Indianapolis, Indiana-based Point Biopharma, an 87% premium to the group's Monday closing share price The deal adds to Eli Lilly's growing oncology portfolio, which was jump-started in 2019 with the $8 billion takeover of cancer treatment specialists Loxo Oncology "Over the past few years, we have seen how well-designed radiopharmaceuticals can demonstrate meaningful results for patients with cancer and rapidly integrate into standards of care, yet the field remains in the early days of the impact it may ultimately deliver," said Eli Lilly's Jacob Van Naarden, who heads the group's oncology unit and was formerly COO of Loxo. "We are excited by the potential of this emerging modality and see the acquisition of POINT as the beginning of our investment in developing multiple meaningful radioligand medicines for hard-to-treat cancers, as we have done in small molecule and biologic oncology drug discovery and development." "We look forward to welcoming POINT colleagues to Lilly and working together to build upon their achievements as we develop a pipeline of meaningful new radioligand treatments for patients," he added. Point Biopharma shares were marked 84.45% higher in pre-market trading following news of the takeover to indicate an opening bell price of $12.35 each. Eli Lilly shares, meanwhile, slipped 0.05% to $538.00 each.Get exclusive access to portfolio managers and their proven investing strategies with Real Money Pro. Get started now.
[Read more...](https://www.thestreet.com/investing/stocks/point-biopharma-global-stock-soars-on-1-4-takeover-bid-from-eli-lilly)
Point Biopharma stock soars on $1.4B takeover bid from Eli Lilly

Point Biopharma Global (PNT) - Get Free Report shares soared in premarket trading after the radiation-therapies experts agreed to a $1.4 billion takeover by pharma giant Eli Lilly (LLY) - Get Free Report. Eli Lilly said it will pay $12.50 per share in cash for Indianapolis, Indiana-based Point Biopharma, an 87% premium to the group's Monday closing share price The deal adds to Eli Lilly's growing oncology portfolio, which was jump-started in 2019 with the $8 billion takeover of cancer treatment specialists Loxo Oncology "Over the past few years, we have seen how well-designed radiopharmaceuticals can demonstrate meaningful results for patients with cancer and rapidly integrate into standards of care, yet the field remains in the early days of the impact it may ultimately deliver," said Eli Lilly's Jacob Van Naarden, who heads the group's oncology unit and was formerly COO of Loxo. "We are excited by the potential of this emerging modality and see the acquisition of POINT as the beginning of our investment in developing multiple meaningful radioligand medicines for hard-to-treat cancers, as we have done in small molecule and biologic oncology drug discovery and development." "We look forward to welcoming POINT colleagues to Lilly and working together to build upon their achievements as we develop a pipeline of meaningful new radioligand treatments for patients," he added. Point Biopharma shares were marked 84.45% higher in pre-market trading following news of the takeover to indicate an opening bell price of $12.35 each. Eli Lilly shares, meanwhile, slipped 0.05% to $538.00 each.Get exclusive access to portfolio managers and their proven investing strategies with Real Money Pro. Get started now.
Read more...
*10 high conviction stocks: Goldman Sachs*

Now may not be the best time to load up on stocks. The forward price-earnings ratio for the S&P 500 registered 17.9 as of Friday, according to FactSet. That’s close to the 5-year average of 18.7 and the 10-year average of 17.5. So it may be a good time to leave your stock weighting where it is. But if you do want to increase your exposure to stocks, here are 10 well-known names on Goldman Sachs’ list of 24 high-conviction stocks. They’re in alphabetical order. Amazon AMZNApple AAPLChevron CVXFirst Solar FSLR, a solar panel makerJPMorgan Chase JPMMerck MRKNvidia NVDAPPG Industries PPG, a coatings companyRepublic Services RSG, the second-largest U.S. solid waste services companyWarner Brothers Discovery, the entertainment company WBDMorningstar Commentary Amazon Moat (competitive advantage) rating: wide. Fair value estimate: $150. Monday’s closing price: $128.95. “We are maintaining our fair value estimate, as the Federal Trade Commission and 17 state attorneys general filed a lawsuit against the company for a variety of alleged anticompetitive practices,” wrote Morningstar analyst Dan Romanoff. “Our initial opinion is that a settlement is the most likely outcome, with a fine being levied and possibly some minor changes in business practices. We are highly skeptical that Amazon will be broken up.” The lawsuit aside, “Amazon dominates its served markets, notably e-commerce and cloud services,” Romanoff said. “It benefits from numerous competitive advantages and has emerged as the clear e-commerce leader, thanks to its size and scale.” Apple Moat rating: wide. Fair value estimate: $150. Monday’s closing price: $173.75. “We maintain our fair value estimate after the company announced its annual update to its iPhones and watches,” wrote Morningstar analyst Brian Colello. “We’re delighted with Apple’s innovation within these devices, as the firm continues to show off its cumulative expertise (and competitive advantage) in hardware, software, services, and semiconductors.” But Colello still views Apple shares as modestly overvalued, because he anticipates only mid-single-digit revenue growth over the next few years. Still, “Apple’s consumer hardware dominance stems from its ability to package [all its hardware and software] into appealing devices,” he said. JPMorgan Moat rating: wide. Fair value estimate: $153. Monday’s closing price: $143.75. “The bank entered the second half of 2023 in a strong position,” wrote Morningstar analyst Eric Compton.” “Its adjusted return of tangible common equity of 23% [in the first quarter] reinforces our wide moat rating and the fact that the bank's fundamentals are some of the strongest under our coverage.” Compton didn’t hold back praise from the bank. “JPMorgan Chase is arguably the most dominant bank in the U.S.,” he said “With leading investment bank, commercial bank, credit card, retail bank, and asset and wealth management franchises, JPMorgan is truly a force to be reckoned with.” The author of this story owns shares of Amazon, Apple, and JPMorgan.
[Read more...](https://www.thestreet.com/stocks/10-favorite-stocks-goldman-sachs)
10 high conviction stocks: Goldman Sachs

Now may not be the best time to load up on stocks. The forward price-earnings ratio for the S&P 500 registered 17.9 as of Friday, according to FactSet. That’s close to the 5-year average of 18.7 and the 10-year average of 17.5. So it may be a good time to leave your stock weighting where it is. But if you do want to increase your exposure to stocks, here are 10 well-known names on Goldman Sachs’ list of 24 high-conviction stocks. They’re in alphabetical order. Amazon AMZNApple AAPLChevron CVXFirst Solar FSLR, a solar panel makerJPMorgan Chase JPMMerck MRKNvidia NVDAPPG Industries PPG, a coatings companyRepublic Services RSG, the second-largest U.S. solid waste services companyWarner Brothers Discovery, the entertainment company WBDMorningstar Commentary Amazon Moat (competitive advantage) rating: wide. Fair value estimate: $150. Monday’s closing price: $128.95. “We are maintaining our fair value estimate, as the Federal Trade Commission and 17 state attorneys general filed a lawsuit against the company for a variety of alleged anticompetitive practices,” wrote Morningstar analyst Dan Romanoff. “Our initial opinion is that a settlement is the most likely outcome, with a fine being levied and possibly some minor changes in business practices. We are highly skeptical that Amazon will be broken up.” The lawsuit aside, “Amazon dominates its served markets, notably e-commerce and cloud services,” Romanoff said. “It benefits from numerous competitive advantages and has emerged as the clear e-commerce leader, thanks to its size and scale.” Apple Moat rating: wide. Fair value estimate: $150. Monday’s closing price: $173.75. “We maintain our fair value estimate after the company announced its annual update to its iPhones and watches,” wrote Morningstar analyst Brian Colello. “We’re delighted with Apple’s innovation within these devices, as the firm continues to show off its cumulative expertise (and competitive advantage) in hardware, software, services, and semiconductors.” But Colello still views Apple shares as modestly overvalued, because he anticipates only mid-single-digit revenue growth over the next few years. Still, “Apple’s consumer hardware dominance stems from its ability to package all its hardware and software into appealing devices,” he said. JPMorgan Moat rating: wide. Fair value estimate: $153. Monday’s closing price: $143.75. “The bank entered the second half of 2023 in a strong position,” wrote Morningstar analyst Eric Compton.” “Its adjusted return of tangible common equity of 23% in the first quarter reinforces our wide moat rating and the fact that the bank's fundamentals are some of the strongest under our coverage.” Compton didn’t hold back praise from the bank. “JPMorgan Chase is arguably the most dominant bank in the U.S.,” he said “With leading investment bank, commercial bank, credit card, retail bank, and asset and wealth management franchises, JPMorgan is truly a force to be reckoned with.” The author of this story owns shares of Amazon, Apple, and JPMorgan.
Read more...
*ESPN's NBA coverage influenced by rivalry between Woj and Shams, per report*

The sports media cycle has several big names that have had their public feuds, from Stephen A. Smith and Dan Le Batard to Shannon Sharpe and Skip Bayless. Most of those feuds have been, to an extent, cordial. Smith and Le Batard — who recently quarrelled about the evolution of the sports media landscape — didn't forget to compliment the other during their conversation. Sharpe, who left Bayless at FS1 to join Smith on ESPN, has also reminded fans of his respect for his former colleague. But the rivalry between two Senior NBA Insiders — Adrian Wojnarowski of ESPN and Shams Charania of The Athletic — is reportedly a lot less amiable than the others. The rivalry's attachment to two of sports media's biggest media entities has caused some uneasiness within the reporting at both companies, according to a report by The Washington Post's Ben Strauss.Related: Ex-ESPN analyst agrees with new problematic reason that Stephen A. Smith and Max Kellerman split Wojnarowski, who is colloquially known as "Woj," and Charania, commonly referred to by his first name, are the two most prominent reporters in the space when it comes to breaking news. Both ESPN and The Athletic tend to build their stories and coverage around the news that their respective insider's break. But The Post reports that there has been "tension" at ESPN because of Woj's influence. The report stated that some reporters "feel they should avoid stories that could be unfavorable to a Woj source." ESPN declined to comment to TheStreet on The Washington Post story.Related: ESPN to launch new football program featuring a controversial former NFL coach The Times recently scrapped its sports department, paving the way for the company's sports coverage to come from The Athletic which the company acquired for $550 million in 2022. But some newsroom staffers at The Times have reportedly had issues with Charania's ability to remain impartial because of his affiliation with FanDuel, a sports gambling company. That issue had been raised in the company slack channel, to which The Athletic's publisher David Perpich reportedly responded by saying it's standing behind Charania's work while also working to "elevate guidelines." Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
[Read more...](https://www.thestreet.com/media/espns-nba-coverage-woj-shams-rivalry)
ESPN's NBA coverage influenced by rivalry between Woj and Shams, per report

The sports media cycle has several big names that have had their public feuds, from Stephen A. Smith and Dan Le Batard to Shannon Sharpe and Skip Bayless. Most of those feuds have been, to an extent, cordial. Smith and Le Batard — who recently quarrelled about the evolution of the sports media landscape — didn't forget to compliment the other during their conversation. Sharpe, who left Bayless at FS1 to join Smith on ESPN, has also reminded fans of his respect for his former colleague. But the rivalry between two Senior NBA Insiders — Adrian Wojnarowski of ESPN and Shams Charania of The Athletic — is reportedly a lot less amiable than the others. The rivalry's attachment to two of sports media's biggest media entities has caused some uneasiness within the reporting at both companies, according to a report by The Washington Post's Ben Strauss.Related: Ex-ESPN analyst agrees with new problematic reason that Stephen A. Smith and Max Kellerman split Wojnarowski, who is colloquially known as "Woj," and Charania, commonly referred to by his first name, are the two most prominent reporters in the space when it comes to breaking news. Both ESPN and The Athletic tend to build their stories and coverage around the news that their respective insider's break. But The Post reports that there has been "tension" at ESPN because of Woj's influence. The report stated that some reporters "feel they should avoid stories that could be unfavorable to a Woj source." ESPN declined to comment to TheStreet on The Washington Post story.Related: ESPN to launch new football program featuring a controversial former NFL coach The Times recently scrapped its sports department, paving the way for the company's sports coverage to come from The Athletic which the company acquired for $550 million in 2022. But some newsroom staffers at The Times have reportedly had issues with Charania's ability to remain impartial because of his affiliation with FanDuel, a sports gambling company. That issue had been raised in the company slack channel, to which The Athletic's publisher David Perpich reportedly responded by saying it's standing behind Charania's work while also working to "elevate guidelines." Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
Read more...
*Apple Pencil 3 получит сменные наконечники для разных стилей рисования*

Девайс превратится в настоящую кисть для скетчей, живописи и черчения.
[Read more...](https://lifehacker.ru/apple-razrabatyvaet-pencil-3/)